This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Umezawa H US 4,029,547, zit. nach (1981) Drugs Fut 6:604-606
Umezawa H, Aoyagi T, Shirai T, Nishizawa R, Suzuki M, Saino T Bit 2,037,754; Ger Offen 2,947,140; Jpn K 80 72,151 und 80 79,353; Neth Appl 7,908,510, zit. nach Drugs Fut (1981) 6:604-606
Nishizawa R, Tetsushi S, Suzuki M, Fujii T, Shirai T, Aoyagi T, Umezawa H (1983) J Antibiotics 36:695–699
Nishizawa R, Saino T, Takita T, Suda H, Aoyagi T, Umezawa H (1977) J Med Chem 20:510–515
Kobayashi S, Isobe T, Ohno M (1984) Tetrahedron Lett 25:5079–5082
Ricci JS, Bousvaros A, Taylor A (1982) J Org Chem 47:3063–3065
Suda H, Takita T, Aoyagi T, Umezawa H (1976) J Antibiotics 26:100–101
Nempto K, Abe F, Karakawa K, Horinishi H, Umezawa H (1987) Enhancement of colony formation of mouse bone marrow cells by ubenimex. J Antibiot Tokyo 40(6):894–898
Shibuya K, Hayashi E, Abe F, Takahashi K, Horinishi H, Ishizuka M, Takeuchi T, Umezawa H (1987) Enhancement of interleukin 1 and interleukin 2 release by ubenimex. J Antibiot Tokyo 40(3):363–369
Ueda T, Tohyama K, Wano Y, Tsutani H, Fukushima T, Iwasaki H, Urasaki Y, Gotoh N, Kimura S, Okumura E, et al. (1994) Pharmacokinetic and clinical pilot study of high-dose intermittent ubenimex treatment in patients with myelodysplastic syndrome. Anticancer Res 1994 Sep-Oct; 14(5B):2093–2097
Ota K, Ogawa N (1990) Randomized controlled study of chemoimmunotherapy with bestatin of acute nonlympho-cytic leukemia in adults. Biomed-Pharmacother. 44(2):93–101
Ota K (1991) Review of ubenimex (Bestatin): clinical research. Biomed-Pharmacother 45(2–3):55–60
Keinan E, Eren D (1988) Pure Appl Chem 60(1):89–98
Kanazawa M, Takahashi T (1981) Biomed Clin Aspects Coenzyme Q 3:31–42, zit. nach CA (1982) 96(13):102355u
Shi H (1985) Yaoxue Tongbao 20(12):741–743, zit. nach CA(1986) 104(18):155762q
Al-Shora HI (1987) Pharmazie 42:56–57
Morton RA (1991) Ubiquinones, plastoquinones and vitamin K. Biol Rev 46:47–96
McCord JM (1988) Free radicals and myocardial ischemia: overview and outlook. Free Rad Biol 4:9–16
Spinsi A, Masotti L, Lenaz G, Bertoli E, et al. (1978) Interaction between ubiquinones and phospolipid bilayers. Arch Biochem Biophys 190:454–462
Greenberg S, Frishman WH (1990) Co-enzyme Q10: a new drug for cardiovascular disease. J Clin Pharmacol 30:596–608
Saupe J, Ronden JE, Soute BAM, Vermeer C (1994) Vitamin K-antagonistic effect of plastoquinone and ubiqui-none derivatives. FEBS Lett 334:143–146
Spigset O (1994) Reduced effect of warfarin caused by ubidecarenone. Lancet 344:1372–1373
Yumada S, Oyama M, Yuki Y, Kato K, Suyahara K (1995) Eur J Biochem 233:687–693; zit. nach CA 124:254164
Toyoda H, Kobayashi S, Sakamoto S, Toida T, Imanari T (1993) Biol Pharm Bull 16:945–947
Toyoda H, Ikei T, Demachi Y, Toida T, Imanari T (1992) Chem Pharm Bull 40:2882–2884
JP 09048798 A2 970218 Heisei; zit. nach CA 126:199839
Yan J, Dai C, Zhum J, Zhang X, Gou X, Zhany P; zit nach Ca 118:27325
Shikimi T, Suzuki S, Takahashi M, Kaneto H (1990) Scand J Clin Lab Invest 50:1–8; zit. nach CA 112:212784
Suzuki S, Takuada K, JP 94-338313 941229; zit. nach CA 125:177341
Doi N, Hayashi T, Morita K; JP 92-325888 921023; zit. nach CA 121:164038
Nishijima J, Hiraoka N, Murata A, Oka Y, et al. (1992) Protease inhibitors (gebexate mesylate and ulinastatin) stimulate intracellular chemiluminescence in human neutro-phils. J Leukoc Biol 52:262–268
Kawamura T, Wakusawa R (1990) The effect of ulinastatin on the release of granulocyte elastase during hypothermia with surface cooling. Can J Anaesth 37:S106
Endo S, Inada K, Yamashita H, Takakuwa T, et al. (1993) The inhibitory actions of protease inhibitors on the production of polymorphonuclear leukocyte elastase and in-terleukin 8: Res Commun Chem Pathol Pharmacol 82:27–34
Kudo Y, Egashira T, Yamanaka Y (1992) Protective effect of ulinastatin against liver injury caused by ischemia-re-perfusion in rats. Jpn J Pharmacol 60:239–245
Endo S, Inada K, Taki K, Hoshi S, et al. (1990) Inhibitory effects of ulinastatin on the production of cytokines: Implications for the prevention of septicemic shock. Clin Ther 12:323–326
Nishimura K, Kumada K, Okamoto R, Ban T (1991) Effects of ulinastatin in experimental acute arterial occlusion in rats. Eur J Surg 157:115–116
Okamoto T, Inagaki Y, Aoki T (1993) Use of ulinastatin for improving the viability of liver grafts. Transplant Proc 25:2961–2964
Binns OA, De Lima NF, Buchanan SA, Mauney MC, et al. (1996) Neutrophil endopeptidase inhibitor improves pulmonary function during reperfusion after eighteen-hour preservation. J Thorac Cardiovasc Surg 112:607–613
Tani T, Aoki H, Yoshioka T, Lin KJ, et al. (1993) Treatment of septic shock with a protease inhibitor in a canine model: a prospective, randomized, controlled trial. Crit Care Med 21:925–930
Okano S, Tagawa M, Urakawa N, Ogawa R (1994) A therapeutic effect of ulinastatin on endotoxin-induced shock in dogs-comparison with methylprednisolon. J Vet Med Sci 56:645–649
Shimai S, Takano T, Seino Y, Tanaka K, et al. (1989) Role of PMN elastase on ischemie myocardial injury in evol ving myocardial infarction: correlation with clinical parameters and intervention by protease inhibitor ulinastatin. Jpn Circ J 53:1144–1151
Kawamura K, Inada K, Akasaka N, Wakusawa R (1996) Ulinastatin reduces elevation of cytokines and soluble adhesion molecules during cardiac surgery. Can J Anaesth 43:456–460
Hiyama A, Takeda J, Kotake Y, Morisaki H, et al. (1997) A human urinary protease inhibitor (ulinastatin) inhibits neutrophil extracellular relase of elastase during cardio-pulmonary bypass. J Cardiothorac Vasc Anesth 11:580–584
Drags Fut (1991) 16(5):437-442
Ahlenius S, Wijkstrom A (1992) Mixed agonist-antagonist properties of umespirone at neostriatal dopamine receptors in relations to its behavioural effects in the rat. Eur J Pharmacol 222:69–74
Barnes NM, Costall B, Comeney AM, Gerrard PA, Kelly ME, Krahling H, Naylor RJ, Tomkins DM, Williams TJ (1991) The effects of umespirone as a potential anxiolytic and antipsychotic agent. Pharmacol Biochem Behav 40:86–96
Holland RL, Wesnes K, Dietrich B (1994) Single dose human pharmacology of umespirone. Eur J Clin Pharmacol 1994 46(5):461–468
Itzhak Y, Ruhland M, Krahling H (1990) Binding of umespirone to the sigma receptor: evidence for multiple affinity states. Neuropharmacology 29:181–184
Rewo Chem. Fabrik GmbH (1968) Pat Fr 1546581, zit. nach CA (1970) 72:P12152a
Lyddon FE, Gundersen K, Maibach HI (1980) Short chain fatty acids in the treatment of dermatophytoses, Int J Der-matol 19, 24–28
Drugs Fut (1992) 17(3): 193-196
Mar31,S. 1462
Drugs Fut (1989) 490:411-417
Schulz-Knappe P, Forssmann K, Herbst F, Hock D, Pip-korn R, Forssmann WG (1988) Isolation and structural analysis of „urodilatin„, a new peptide of the cardiodila-tion — (ANP) — family extracted from human urine. Klin Wochenschr 66, 752–759
Feller SM, Gagelmann M, Forssmann WG (1989) Urodilatin: a newly described member of the ANP family. TIPS 10, 93–94
Heim JM, Kiefersauer S, Fülle HJ, Gerzer R (1989) Urodilatin and beta ANF binding properties and activation of particulate guanylate cyclase. Biochem Biophys Res Commun 163, 37–41
Saxenhofer H, Raselli A, Weidmann P, Forssmann WG, Bub A, Ferrari P, Shaw SG (1990) Urodilatin, a natriuretic factor from kidneys, can modify renal and cardiovascular function in men. Am J Physiol 259, F832–F838
Flüge T, Fabel H, Wagner TOF, Schneider B, Forssmann WG (1995) Urodilatin (Ularitide, INN): a potent broncho-dilator in asthmatic subjects. Europ J Clin Invest 25:728–736
Gutkowska J, Antunes-Rodrigues J, McCann SM (1997) Atrial natriuretic peptide in brain and pituitary gland. Physiol Rev 77, 479–483
Drew A, Hildebrandt H, Leland Mizelle, Brands MW, Hall JE (1992) Comparison of renal actions of urodilatin and atrial natriuretic peptide. Am J Physiol 262:R395–R399
Drummer C, Fiedler F, Bub A, Kleefeld D, Dimitriades E, Gerzer R, Forssmann WG (1993) Development and application of a urodilatin (CDD-ANP95-126)-specific radio-immunoassay. Pflügers Arch 423:372–377
McKinley MJ, Denton DA, Nelson JF, Weisinger RS (1983) Cerebral involvement in dehydration-induced na-triuresis. Brain Res 264:340–343.
Emmeluth C, Gretz KL, Drummer C, Gerzer R, Forss-mann WG, Bie P (1996) Natriuresis caused by increased carotid NA-concentration after renal denervation. Am J Physiol 270:F510–F517
Gagelmann M, Hock D, Forssmann WG (1988) Urodilatin (CDD/ANP95-126) is not biologically inactivated by a peptidase from dog kidney cortex membranes in contrast to atrial natriuretic peptide/cardiodilatin (a-hANP/ CDD99-126). FEBS LETT 233:249–254
Kentsch M, Ludwig D, Drummer C, Gerzer R, Miiller-Esch G (1992) Haemodynamic and renal effects of urodilatin in healthy volunteers. Eur J Clin Invest 22:319–325
Drummer C, Kentsch M, Otter W, Heer M, Herten M, Gerzer R (1997) Increased renal natriuretic peptide (urodilatin) excretion in heart failure. Eur J Med Res 2:347–354
Shaw S, Weidmann P, Zimmermann A (1992) Urodilatin, not nitroprusside, combined with dopamine reverses ischemie acute renal failure. Kidney Int 42:1153–1159
Cecidi C, Kuse ER, Meyer M (1993) Treatment of acute postoperative renal failure after liver and heart transplantation by urodilatin. Clin Invest 71:435–436
Hummel M, Kuhn M, Bub A, Mann B, Schneider B, von Eickstedt KW, Forssmann WG, Hetzer R (1993) Urodilatin, a new therapy to prevent kidney failure after heart transplantation. J Heart Lung, Transplant 12:209–217
Laws H-J, Kropp S, Meyer M, Forssmann WG, Burdach S (1995) Treatment of acute renal failure with urodilatin after unrelated bone marrow transplantation in an 18-month old boy. Bone Marrow Transplantation 16:307–331
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
von Bruchhausen, F. et al. (1999). U. In: von Bruchhausen, F., et al. Hagers Handbuch der Pharmazeutischen Praxis. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-58388-9_10
Download citation
DOI: https://doi.org/10.1007/978-3-642-58388-9_10
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-63569-4
Online ISBN: 978-3-642-58388-9
eBook Packages: Springer Book Archive